Anavex receives EMA filing acceptance for treatment of Alzheimer’s disease

Anavex (AVXL) Life Sciences announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorization Application, MAA, for blarcamesine, ANAVEX 2-73, an investigational drug for the treatment of Alzheimer’s disease. The Company is looking forward to working with the EMA. “The EMA filing acceptance for blarcamesine to review the Marketing Authorization Application potentially brings us a step closer offering broader patient access to a new treatment option in Europe, and we look forward to continued engagement with the EMA,” said Juan Carlos Lopez-Talavera, MD, PhD, Head of Research and Development of Anavex. “Through our clinical development program, we have seen that blarcamesine has the potential to slow the progression of this relentless and ultimately fatal disease.”